Luis Felipe Montano

Dr. Luis Felipe Montano

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SDSANYOG DWIVEDI
SANYOG DWIVEDI
ERErika Patricia Rendón-Huerta
Erika Patricia Rendón-Huerta
Vianney Ortiz-NavarreteVianney Ortiz-Navarrete
Vianney Ortiz-Navarrete
LMLuis Felipe Montano
Luis Felipe Montano
Cancer is a leading cause of death worldwide. Understanding the functional mechanisms associated with metabolic reprogramming, which is a typical feature of cancer cells, is key to effective therapy. CD38, primarily a NAD+glycohydrolase and ADPR cyclase, is a multifunctional transmembrane protein whose abnormal overexpression in a variety of tumor types is associated with cancer progression. It is linked to VEGFR2 mediated angiogenesis and immune suppression as it favors the recruitment of suppressive immune cells like Tregs and myeloid-derived suppressor cells, thus helping immune escape. CD38 is expressed in M1 macrophages and in neutrophil and T cell-mediated immune response and is associated with IFNγ-mediated suppressor activity of immune responses. Targeting CD38 with anti-CD38 monoclonal antibodies in hematological malignancies has shown excellent results. Bearing that in mind, targeting CD38 in other nonhematological cancer types, especially carcinomas, which are of epithelial origin with specific anti-CD38 antibodies alone or in combination with immunomodulatory drugs, is an interesting option that deserves profound consideration.

11 December 2017 in Journal of Immunotoxicology
Verified
Journal Article
Open access
FGFrancisco Gallardo-Vera
Francisco Gallardo-Vera
MTMiguel Tapia-Rodriguez
Miguel Tapia-Rodriguez
Daniel DiazDaniel Diaz
Daniel Diaz
TFTeresa I. Fortoul
Teresa I. Fortoul
LMLuis Felipe Montano
Luis Felipe Montano
ERErika P. Rendón-Huerta
Erika P. Rendón-Huerta
Vanadium is an air pollutant that imparts immunosuppressive effects on NK cell immune responses, in part, by dysregulating interleukin (IL)-2/IL-2R-mediated JAK signaling pathways and inducing apoptosis. The aim of the present study was to evaluate effects of vanadium pentoxide (V2O5) on other IL-2 receptor-mediated signaling pathways, i.e. PI3K-AKT-mTOR and Ras-MAPK. Here, IL-2-independent NK-92MI cells were exposed to different V2O5 doses for 24 h periods. Expression of PI3K, Akt, mTOR, ERK1/2, MEK1, PTEN, SHP1, BAD and phosphorylated forms, as well as caspases-3, -8, -9, BAX and BAK in/on the cells were then determined by flow cytometry. The results show that V2O5 was cytotoxic to NK cells in a dose-related manner. Exposure increased BAD and pBAD expression and decreased that of BAK and BAX, but cell death was not related to caspase activation. At 400 µM V2O5, expression of PI3K-p85 regulatory subunit increased 20% and pPI3K 50%, while that of the non-pPI3K 110α catalytic subunit decreased by 20%. At 200 μM, V2O5 showed significant decrease in non-pAkt expression (p < 0.05); the decrease in pAkt expression was significant at 100 μM. Non-pmTOR expression displayed a significant downward trend beginning at 100 μM. Expressions of pMEK-1/2 and pERK-1/2 increased substantially at 200 μM V2O5. No differences were found with non-phosphorylated ERK-1/2. PTEN expression increased significantly at 100 μM V2O5 exposure whereas pPTEN decreased by 18% at 25 μM V2O5 concentrations, but remained unchanged thereafter. Lastly, V2O5 at all doses decreased SHP1 expression and increased expression of its phosphorylated form. These results indicated a toxic effect of V2O5 on NK cells that was due in part to dysregulation of signaling pathways mediated by IL-2 via increased PTEN and decreased SHP1 expression. These results can help to explain some of the known deleterious effects of this particular form of vanadium on innate immune responses.

30 June 2006 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
NANoé Alvarado‐Vásquez
Noé Alvarado‐Vásquez
APAraceli Páez
Araceli Páez
EZEstrella Zapata
Estrella Zapata
SASusana Alcázar‐Leyva
Susana Alcázar‐Leyva
EZEdgar Zenteno
Edgar Zenteno
LMLuis Felipe Montano
Luis Felipe Montano

Verified
Journal Article
Open access
PDF file
SDSANYOG DWIVEDI
SANYOG DWIVEDI
GHGeorgina Hernández-Montes
Georgina Hernández-Montes
LMLuis Felipe Montano
Luis Felipe Montano
ERErika Patricia Rendón-Huerta
Erika Patricia Rendón-Huerta
(1) Abnormally increased expression of claudin-6 in gastric cancer is considered a prognostic marker of the chromosomal unstable molecular subtype. However, a detailed molecular profile analysis of differentially expressed genes and affected pathways associated with claudin-6 increased (Cldn6high) expression has not been assessed. (2) The TCGA Stomach Adenocarcinoma Pan-Cancer Atlas Data was evaluated using Cytoscape’s Gene Mania, MCODE, and Cytohubba bioinformatic software. (3) 96.88% of Cldn6high gastric cancer tumors belonging to the chromosomal unstable molecular subtype are associated with a worse prognosis. Cldn6expression coincided with higher mutations in TP53, MIEN1, STARD3, PGAP3, and CCNE1 genes compared to Cldn6low expression. In Cldn6high cancers, 1316 genes were highly expressed. Cholesterol metabolism was the most affected pathway as APOA1, APOA2, APOH, APOC2, APOC3, APOB-100, LDL receptor-related protein 1/2, Sterol O-acyltransferase, STARD3, MAGEA-2, -3, -4, -6, -9B, and -12 genes were overexpressed in Cldn6high gastric cancers; interestingly, APOA2 and MAGEA9b were identified as top hub genes. Functional enrichment of DEGs linked HNF-4α and HNF-1α genes as highly expressed in Cldn6high gastric cancer. (4) Our results suggest that APOA2 and MAGEA9b could be considered as prognostic markers for Cldn6high gastric cancers.

15 August 2007 in Immunology Letters
Verified
Journal Article
Closed access
AMAdolfo René Méndez‐Cruz
Adolfo René Méndez‐Cruz
APAraceli Paez-Arenas
Araceli Paez-Arenas
RJRafael Jimenez-Flores
Rafael Jimenez-Flores
JRJulia Reyes-Reali
Julia Reyes-Reali
EVElvira Varela
Elvira Varela
LMLuis Felipe Montano
Luis Felipe Montano

Verified
Journal Article
Open access
PDF file
RRRomero-Estrada Romero-Estrada
Romero-Estrada Romero-Estrada
LMLuis Felipe Montano
Luis Felipe Montano
ERErika Patricia Rendón-Huerta
Erika Patricia Rendón-Huerta
Aberrant expression of the tight junction protein claudin 6 (CLDN6) is a hallmark of gastric cancer progression. Its expression is regulated by the cAMP response element-binding protein (CREB). In gastric cancer induced by Helicobacter pylori (H. pylori) there is no information regarding what transcription factors induce/upregulate the expression of CLDN6. We aimed to identify whether CREB and Yin Yang1 (YY1) regulate the expression of CLDN6 and the site where they bind to the promoter sequence. Bioinformatics analysis, H. pylori lipopolysaccharide (LPS), YY1 and CREB silencing, Western blot, luciferase assays, and chromatin immunoprecipitation experiments were performed using the stomach gastric adenocarcinoma cell line AGS. A gen reporter assay suggested that the initial 2000 bp contains the regulatory sequence associated with CLDN6 transcription; the luciferase assay demonstrated three different regions with transcriptional activity, but the −901 to −1421 bp region displayed the maximal transcriptional activity in response to LPS. Fragment 1279–1421 showed CREB and, surprisingly, YY1 occupancy. Sequential Chromatin Immunoprecipitation (ChIP) experiments confirmed that YY1 and CREB interact in the 1279–1421 region. Our results suggest that CLDN6 expression is regulated by the binding of YY1 and CREB in the 901–1421 enhancer, in which a non-described interaction of YY1 with CREB was established in the 1279–1421 region.